Cited by 31

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Lp(a) Levels and Atherosclerotic Vascular Disease in a Sample of Patients With Familial Hypercholesterolemia Sharing the Same Gene Defect

Carmena, Rafael, Lussier-Cacan, Suzanne, Roy, Madeleine, Minnich, Anne, Lingenhel, Arno, Kronenberg, Florian, Davignon, Jean·1996·Arteriosclerosis, Thrombosis, and Vascular Biology

Abstract

Abstract There is considerable variation in the severity of cardiovascular disease among patients with familial hypercholesterolemia (FH). Some reports have suggested that plasma lipoprotein(a) [Lp(a)] levels may explain such variation and that FH subjects deficient in LDL receptors, especially those with coronary heart disease, tend to have elevated Lp(a) levels. We have investigated the possible role of the LDL receptor in determining plasma Lp(a) levels in a genetically homogeneous FH population and the contribution of Lp(a) to cardiovascular risk. A total of 98 FH subjects and 66 healthy first- and second-degree relatives from 30 families with FH due to the French-Canadian >10-kilobase deletion of the LDL receptor gene were studied. A reference group of 392 normolipidemic French-Canadian participants in a Heart Health Survey was used for comparison. FH subjects were subdivided into subsets of 63 individuals free from atherosclerotic vascular disease (AVD) and 35 individuals with AVD. A complete cardiovascular evaluation was performed, and plasma lipid, lipoprotein, and Lp(a) levels were measured in all subjects in the absence of medication. Apolipoprotein (a) [apo(a)] phenotype was determined in 112 of FH and non-FH subjects. The log-transformed values for plasma Lp(a) were not significantly different among the three groups: 0.98±0.54 (mean±SD) in FH subjects with AVD, 0.89±0.51 in FH subjects without AVD, and 0.82±0.64 in their relatives. The distribution of the apo(a) phenotypes did not differ between the FH and non-FH groups. Comparison of two age- and sex-matched subgroups of FH subjects, with and without AVD, failed to show any differences in Lp(a) level. However, mean Lp(a) log values in the reference group (n=392) were significantly lower than values obtained for the total FH group (0.79±0.57 versus 0.92±0.52, respectively;P<.05) but were not different from those of the unaffected family members. Thus, in our sample, the LDL receptor appears not to influence plasma Lp(a) levels; rather, these levels reflect shared apo(a) genes. The cardiovascular risk in this group of subjects with FH was related to age, male sex, total and LDL cholesterol, and higher apoB but not Lp(a) levels.

Overview

Integrity signals

Registry

Crossref · 10.1161/01.atv.16.1.129

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Other studies of individuals with Familial Hypercholesterolemia have not reported an increase in Lp(a) levels.

    “Some studies of individuals with Familial Hypercholesterolemia (FH) have reported an increase in Lp(a) levels40-42, but others have not43-45 and suggested that the former may have been confounded by diagnostic ascertainment bias and/or unequal distributions of LPA risk alleles between FH and non-FH populations44,45.”

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 52

  1. 10.1161/01.CIR.74.4.758 · DOI
  2. 10.1001/jama.1986.03380180102027 · DOI
  3. 10.1161/01.ATV.8.4.398 · DOI
  4. 10.1016/0002-9149(91)90862-F · DOI
  5. 10.1161/str.17.5.2945294 · DOI
  6. 10.1161/01.ATV.9.5.593 · DOI
  7. 10.1016/0140-6736(92)92756-6 · DOI
  8. 10.1111/j.1365-2796.1992.tb00596.x · DOI
  9. 10.1016/0021-9150(93)90179-X · DOI
  10. 10.1161/circ.86.2.1386292 · DOI
  11. 10.1016/0014-5793(83)80182-3 · DOI
  12. 10.1126/science.2530631 · DOI · Paper page
  13. 10.1172/JCI114625 · DOI
  14. 10.1172/JCI115855 · DOI
  15. 10.1016/0021-9150(82)90053-3 · DOI
  16. Brewer HB Jr. Effectiveness of diet and drugs in the treatment of patients with elevated Lp(a) levels. In: Scanu AM ed. Lipoprotein(a) . New York NY: Academic Press Inc; 1990:211-220. · DOI
  17. 1985, J Lipid Res, 26, 1314, 10.1016/S0022-2275(20)34257-7 · DOI
  18. 10.1172/JCI114602 · DOI · Paper page
  19. 10.1007/BF01745519 · DOI
  20. 10.1016/0140-6736(90)91242-3 · DOI
  21. 10.1172/JCI110896 · DOI · Paper page
  22. 10.1073/pnas.86.11.4171 · DOI
  23. 10.1016/S0140-6736(88)92884-X · DOI
  24. 10.1161/atv91.11.4.1829633 · DOI
  25. 10.1056/NEJM199005243222104 · DOI
  26. 10.1172/JCI115329 · DOI
  27. 10.1016/0026-0495(92)90163-5 · DOI
  28. 10.1056/NEJM198709173171204 · DOI
  29. Santé Québec. Et votre coeur ça va? Rapport de l’Enquête québécoise sur la santé cardiovasculaire 1990. Montréal Canada: Ministère de la Santé et des Services Sociaux Gouvernement du Québec; 1994:159.
  30. Lipid Research Clinics Program. Manual of Laboratory Operations: Lipid and Lipoprotein Analysis . Washington DC: US Dept of Health Education and Welfare; 1974;1:1-81. US Dept of Health Education and Welfare publication NIH 75-628.
  31. 10.1161/01.ATV.5.6.639 · DOI
  32. 1989, Clin Genet, 36, 219, 10.1111/j.1399-0004.1989.tb03194.x · DOI
  33. 10.1172/JCI116370 · DOI
  34. 10.1016/0021-9150(91)90111-F · DOI
  35. 1990, J Lipid Res, 31, 1247, 10.1016/S0022-2275(20)42633-1 · DOI
  36. 10.1016/0021-9150(92)90279-P · DOI
  37. 10.1172/JCI117794 · DOI · Paper page
  38. 1993, J Biol Chem, 268, 8569, 10.1016/S0021-9258(18)52913-6 · DOI
  39. 10.1161/atv91.12.10.1390593 · DOI
  40. 10.1161/atv91.14.10.7918305 · DOI
  41. 1991, J Lipid Res, 32, 1513, 10.1016/S0022-2275(20)41918-2 · DOI
  42. 1991, Clin Invest Med, 14, 146
  43. 1991, Atherosclerosis Rev, 23, 63
  44. 10.1161/circ.92.3.290 · DOI
  45. 10.1016/0021-9150(91)90007-P · DOI
  46. 10.1016/0021-9150(93)90054-X · DOI
  47. 10.1001/jama.1993.03510180065035 · DOI
  48. 10.1111/j.1365-2362.1994.tb02373.x · DOI
  49. 10.1161/atv91.14.11.7947596 · DOI
  50. 1994, Clin Genet, 46, 42, 10.1111/j.1399-0004.1994.tb04200.x · DOI
  51. 10.1093/clinchem/39.7.1382 · DOI
  52. Naruszewicz M Giroux LM Davignon J. Oxidative modification of lipoprotein(a) causes changes in the structure and biological properties of apo(a). Chem Phys Lipids . 1994;67/68:167-174. · DOI

Cited by

Sorted by citations

Metadata

Authors
Carmena, R., Lussier-Cacan, S., Roy, M., Minnich, A., Lingenhel, A., Kronenberg, F., & Davignon, J.
Affiliations
From the Endocrine Service, Hospital Clinico Universitario, Valencia, Spain (R.C.); the Hyperlipidemia and Atherosclerosis Research Group, Clinical Research Institute of Montreal, Quebec, Canada (S.L.-C., M.R., A.M., J.D.); and the Institute for Medical Biology and Genetics, University of Innsbruck, Innsbruck, Austria (A.L., F.K.).
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
1996-01
Volume
16
Issue
1
Pages
129-136
ISSN
  • 1079-5642
  • 1524-4636
Cited by
31
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review